WEIFANG, China, Dec. 9, 2011 /PRNewswire-Asia-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI)
(''Shengtai'' or ''the Company'' or "we" or "us"), a manufacturer
and distributor in China of
glucose and starch as pharmaceutical raw materials and other starch
and glucose products, today announced that its annual shareholder
meeting ("Meeting") will be held Monday,
February 13, 2012 at 9:00
a.m., local time, at the company's headquarters at Changda
Road East, Development District, Changle County, Shandong, The
People's Republic of China.
Shareholders of record as of January 11,
2012 will be entitled to receive notice of, and vote at, the
Meeting. In addition to this announcement, Shengtai will send a
meeting notice, proxy statement and annual report to all such
shareholders. This press release constitutes a public announcement
of the meeting date. Shareholders who wish to submit nominations of
persons for election to the board of directors or proposals to be
considered at the Meeting should submit such nominations and/or
proposals within 10 days of this announcement in the manner
provided in the Company's bylaws. Such nominations and/or proposals
should be directed to:
c/o Shengtai Pharmaceutical, Inc.
Changda Road East, Development District
Changle County, Shandong,
People's Republic of China
262400
Attn: Nominating Committee
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned
subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating
company of Weifang Shengtai Pharmaceutical Co., Ltd., is a
manufacturer and distributor in china of glucose and starch
products as pharmaceutical raw materials, other starch products and
other glucose products such as corn meals, food and beverage
glucose and dextrin. For more information about Shengtai
Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com.
Forward Looking Statements
Certain statements in this press release and oral statements
made by the Company constitute forward-looking statements
concerning the Company's business and products. These statements
include, without limitation, statements regarding our ability to
prepare the Company for growth, the Company's planned capacity
expansion and predictions and guidance relating to the Company's
future financial performance. We have based these forward-looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs, but they involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand
especially in the pharmaceutical industry, pricing and demand
trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Ms. Yukie Ying Gao
Investor Relations Manager
Tel: 86-536-2188831
Email: ir-yukie@shengtaipharmaceutical.com
SOURCE Shengtai Pharmaceutical, Inc.